Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2023-06-27 00:00:00 ET · period of report 2023-06-26 · accession 0001929354-23-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-06-27 | 2023-06-26 | AVTX | Caissa Capital Management ltd. | 10% | P - Purchase | $0.64 | -1.43M | 0 | -100% | -$912.4K |
| 2023-06-27 | 2023-06-26 | AVTX | Caissa Capital Management ltd. | 10% | P - Purchase | $0.62 | -182.3K | 0 | -100% | -$113.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-26 | P | D | 1,425,700 | $0.64 | 0 | I See Footnote (1) | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.84, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. |
| 2 | Common | Common Stock | 2023-06-26 | P | D | 182,300 | $0.62 | 0 | D | — | — | (F3) These shares are directly owned by Mr. Golestaneh in his personal capacity. |